Finance

Beta
Lists
002727:SHE
Yixintang Pharmaceutical Co Ltd
CN¥11.35
+1.52%
(+0.17) 1D
Jun 5, 3:04:27 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002727...
Open
CN¥11.22
High
CN¥11.48
Low
CN¥11.21
Mkt. cap
6.65B
Avg. vol.
7.17M
Volume
5.05M
Dividend
3.52%
Quarterly dividend
CN¥0.10
Ex-dividend date
May 29, 2026
P/E ratio
23.84
52-wk high
CN¥18.34
52-wk low
CN¥11.08
EPS
CN¥0.48
Shares outstanding
585.60M
No. of employees
35K
Open
CN¥11.22
High
CN¥11.48
Low
CN¥11.21
Mkt. cap
6.65B
Avg. vol.
7.17M
Volume
5.05M
Dividend
3.52%
Quarterly dividend
CN¥0.10
Ex-dividend date
May 29, 2026
P/E ratio
23.84
52-wk high
CN¥18.34
52-wk low
CN¥11.08
EPS
CN¥0.48
Shares outstanding
585.60M
No. of employees
35K
News stories
From sources across the web
About Yixintang Pharmaceutical Co Ltd
CEO-
Employees34.8K
FoundedNov 8, 2000
Headquarters-
SectorDrug
Websitehx8886.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
4.15B
4.09B
4.34B
4.43B
Cost of goods sold
2.83B
2.70B
3.05B
2.97B
Cost of revenue
2.83B
2.70B
3.05B
2.97B
Research and development expenses
5.21M
1.30M
1.57M
797.19K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.22B
1.21B
1.25B
1.20B
Operating expense
1.21B
1.21B
1.30B
1.19B
Total operating expenses
4.04B
3.91B
4.35B
4.15B
Operating income
106.35M
174.68M
-14.76M
281.17M
Other non operating income
-456.74K
-10.37M
7.40M
-543.11K
EBT including unusual items
118.38M
40.85M
43.99M
225.14M
EBT excluding unusual items
79.65M
135.97M
-37.76M
255.65M
Income tax expense
24.03M
19.51M
52.23M
47.31M
Effective tax rate
20.30%
47.75%
118.75%
21.01%
Other operating expenses
5.28M
-26.48M
23.96M
-16.25M
Net income
89.58M
18.94M
-5.16M
175.81M
Net profit margin
2.16%
0.46%
-0.12%
3.97%
Earnings per share
0.15
0.01
-0.01
0.28
Interest and investment income
5.99M
4.32M
3.69M
3.93M
Interest expense
-32.24M
-32.65M
-34.10M
-28.91M
Net interest expenses
-26.25M
-28.34M
-30.40M
-24.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
133.77M
202.06M
12.28M
308.21M
Gain or loss from assets sale
-1.41M
1.41M
-8.79M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer